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Membrane-type 1 matrix metalloproteinase (MT1-
MMP) and vascular endothelial growth factor (VEGF)
are two key molecules involved in pericellular proteol-
ysis and cell proliferation during tumor growth and an-
giogenesis. Our previous data showed that MT1-MMP
overexpression in human breast carcinoma MCF7 cells
induced an up-regulation of VEGF expression. This ef-
fect was associated in vivo with accelerated tumor
growth and angiogenesis. We now provide evidence that
MT1-MMP overexpression specifically affected VEGF-A
production and failed to influence that of other VEGF
family members (VEGF, B, C, D, or PlGF) or their recep-
tors. The up-regulation of VEGF-A by MT1-MMP was
related to an increased transcriptional activation
rather than to a modification of mRNA stability. It was
blocked by synthetic MMP inhibitors, TIMP2, but not
TIMP-1 and abolished by a partial deletion of the cata-
lytic domain or the cytoplasmic tail of MT1-MMP. Anal-
ysis of the signal transduction mechanisms demon-
strated that MT1-MMP acts through a signaling
pathway involving Src tyrosine kinases. Thus, our re-
sults provide new insight into the mechanisms of action
of MT1-MMP during angiogenesis and suggest that the
full enzymatic activity of MT1-MMP is required for a
specific up-regulation of VEGF-A through an activation
of Src tyrosine kinase pathways.
Angiogenesis, the formation of new blood vessels from pre-
existing ones, is a key event in tumor progression controlled by
a balance between positive and negative regulators (1, 2). From
this observation has emerged the concept of the “angiogenic
switch” in which endothelial activation status is determined by
the induction of angiogenic factors and/or the loss of inhibitors
(3). Positive regulators include at least vascular endothelial
growth factor family (VEGF-A, -B, -C, -D),1 fibroblast growth
factors, placental-like growth factor (PlGF), angiopoietins,
their tyrosine kinase receptors (VEGF-R1, -R2; Tie1 and Tie2)
and neuropilin-1 (NRP-1), a co-receptor for VEGF (1, 4). An
increasing number of negative regulators have been identified
such as inhibitors of proteinases, thrombospondins, interfer-
ons, chemokines (IP-10 and PF-4), and bioactive fragments of
the extracellular matrix (2, 4). Once a tumor has acquired an
angiogenic phenotype, tumor cell migration, invasion, and ves-
sel sprouting require the dynamic and coordinated action of
many cell surface molecules, including proteinases and inte-
grins mediating cell-matrix interactions.
Among the cell-associated proteinases, matrix metallopro-
teinases (MMPs) anchored to the plasma membrane, called
membrane-type MMPs (MT-MMPs) play a pivotal role in peri-
cellular proteolysis. Of the six MT-MMPs that have been iden-
tified to date, four (MT1-, MT2-, MT3-, and MT5-MMP) contain
a transmembrane domain followed by a cytoplasmic tail and
two (MT4- and MT6-MMP) are tethered to the cell surface via
a glycosylphosphatidylinositol link (for review, see Refs. 5–8).
It now appears that all MT-MMPs may have the ability to
activate pro-MMP2 (9–13). Although, each of the four physio-
logical tissue inhibitors of MMPs (TIMPs) can non selectively
bind to all active MMPs, TIMP1 is unable to inhibit effectively
MT1, 2, 3, and 5-MMPs (14). TIMP-2 has dual functions, in-
hibiting the activity of each MT-MMP and participating in the
activation of pro-MMP2 through the formation of a ternary
complex formed of MT1-MMP, TIMP-2, and pro-MMP2 (for
review, see Refs. 7, 15, and 16). MMP2 activation by MT1-MMP
could be promoted by interaction with integrin (17) and oli-
gomerization of MT1-MMP (18, 19).
MT1-MMP exerts pleiotropic effects on cell behavior by
cleaving matrix components (20), as well as by controlling
expression and functional status of cell surface receptors, in-
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cluding integrins (21), transglutaminase (22), and CD44 (23).
Numerous studies have demonstrated that it is up-regulated in
aggressive tumors of diverse cell/tissue origin (7, 16). MT1-
MMP has been implicated in the neovascularization process,
because it can act as a potent collagenase and fibrinolysin
promoting tubulogenesis in collagen or fibrin gels (24–26). The
pro-angiogenic activity of MT1-MMP is further supported by
the effects of MT1-MMP overexpression on tumorigenicity,
growth, and vascularization of human melanoma (27), breast
adenocarcinoma (28), or glioma (29) cells transfected with
MT1-MMP cDNA. We have previously provided evidence that
this MT1-MMP pro-angiogenic effect was mediated at least in
part by an up-regulation of VEGF at both mRNA and protein
levels (28). Such a link between the expression of VEGF and
FIG. 1. Influence of MT1-MMP over-
expression on the expression of puta-
tive angiogenic factors and their recep-
tors. MT1-MMP-overexpressing clones (MT
clones: MT/1 and MT/3) and control clones
(C10 and C11) were used to profile by RT-
PCR, the mRNA expression of VEGFs (A, B,
C, D), their receptors (VEGF-R1 and VEGF-
R2), PlGF, neuropilin-1 (NRP-1), angiopoi-
etin-1 (Ang-1), Tie2, and TIMP-2. In some
assays, RNAs isolated from glioblastoma (G)
or placenta (P) have been added as positive
controls. In some cases, for quantification
purpose, synthetic RNAs (CTR1, 2, or 5)
were added in each sample to control the
efficiency of RT-PCR for 28S (CTR1) and
MT1-MMP (CTR1), TIMP-2 (CTR2) and
VEGF-A (CTR5) as described under “Exper-
imental Procedures.” 28 S ribosomal RNA is
shown as a loading control.
TABLE I
Sequence of primers used for RT-PCR studies
Forward primer (53 3) Reverse primer (53 3)
Expected size bp No. of
cyclessRNA mRNA
MT1-MMP 5-GGATACCCAATGCCCATTGGCCA-3 5-CCATTGGGCATCCAGAAGAGAGC-3 269 221 25
TIMP-2 5-CTCGCTGGACGTTGGAGGAAAGAA-3 5-AGCCCATCTGGTACCTGTGGTTCA-3 269 155 25
VEGF-A 5-CCTGGTGGACATCTTCCAGGAGTA-3 5-CTCACCGCCTCGGCTTGTCACA-3 311 275, 407,
and 479
29
VEGF-R1 5-TCCCTTATGATGCCAGCAAGT-3 5-CCAAAAGCCCCTCTTCCAA-3 78 35
VEGF-R2 5-CTTCGAAGCATCAGCATAAGAAACT-3 5-TGGTCATCAGCCCACTGGAT-3 155 35
VEGF-B 5-CAGAGGAAAGTGGTGTCATGGA-3 5-ACCGGATCATGAGGATCTGCA-3 223 35
VEGF-C 5-CTCTCAAGGCCCCAAACCA-3 5-AGGTCTTGTTCGCTGCCTGA-3 151 35
VEGF-D 5-TCTCGCTCAGCATCCCATC-3 5-CACCTCCACGCACGTTTCT-3 152 33
PlGF 5-CCTACGTGGAGCTGACGTTCT-3 5-TCCTTTCCGGCTTCATCTTCT-3 132 35
NRP-1 5-CACAGTGGAACAGGTGATGACTTC-3 5-AACCATATGTTGGAAACTCTGATTGT-3 111 29
Tie-2 5-CAAAACGTGAGGGAAGAACCA-3 5-AAATTGCCCTCCCCAATCA-3 148 35
Ang-1 5-GGAACCGAGCCTATTCACAGTA-3 5-CAAGCATCAAACCACCATCCT-3 211 35
28S 5-GTTCACCCACTAATAGGGAACGTGA-3 5-GATTCTGACTTAGAGGCGTTCAGT-3 269 212 18
MT1-MMP Regulates VEGF through Src Tyrosine Kinase 13565
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
MT1-MMP was further confirmed in authentic tumors, by im-
munohistochemical and RT-PCR analysis of human glioma
tissue samples (30). However, the molecular mechanisms un-
derlying this transcriptional regulation of an angiogenic factor
by a membrane-type MMP is currently unknown. The objec-
tives of this study were to determine whether MT1-MMP reg-
ulates the expression of other angiogenic factors (VEGF-B,
-C,-D, PlGF, and ANG-1 and -2) and their receptors (VEGF-
R1,-R2, NRP-1, and Tie-1 and -2), as well as to provide mech-
anistic insights into VEGF regulation by MT1-MMP.
EXPERIMENTAL PROCEDURES
Reagents and Chemicals—The synthetic MMP inhibitors hydroxamic
acid-based (BB94) (31) or the pyrimidine-2,4,6-trione-type inhibitor (RO
28-2653) (32) were prepared as 10 mM stock solutions in Me2SO and
used at final concentration of 10 M in 0.1% Me2SO. Human recombi-
nant TIMP-1 (rhTIMP-1) and TIMP-2 (rhTIMP-2) were obtained as
described previously (33). Actinomycin D, genistein, and herbimycin A
were from Sigma (St. Louis, MO), PD98059 and SB 203580 were from
Alexis Biochemicals (Lausanne, Suisse), wortmannin and 4-amino-5-(4-
chlorophenyl)-7-(t-butyl)pyrazol[3,4-d]pyrimidine (PP2) were from Cal-
biochem (La Jolla, CA). Aprotinin, leupeptin, and pepstatin A were
obtained from Sigma, and Pefabloc SC (4-(2-aminoethyl)benzenesulfo-
nyl fluoride hydrochloride) was form Roche Diagnostics. Neutralizing
anti-human MT1-MMP monoclonal antibody LEM2/15.8 was generous
gift from Dr. Alicia Arroyo (Madrid, Spain).
cDNA Constructions—Full-length wild type human MT1-MMP
cDNA (huMT1-MMP) without both 5- and 3-untranslated regions was
subcloned between the HindIII and EcoRI sites of pCDNA3.1 Zeo
mammalian expression vector (Invitrogen Ltd., Paisley, UK). Point
mutations (E240A, T567A, C574S, and S577A) were generated by site-
directed mutagenesis using Pfu DNA polymerase (Stratagene, Amster-
dam, The Netherlands). Cytotail truncated MT1-MMP construct (577)
was prepared from full-length MT1-MMP by inserting a stop codon
after Arg-576 by site-directed mutagenesis.
Oligonucleotides coding for huMT1-MMP signal sequence (amino
acids 1–30) were annealed, and the resulting product was cloned up-
stream of EGFP in the NheI-AgeI sites of the pEGFP-C1 vector to
generate the huMT1SSC1 recombinant vector. In the resulting con-
struct the huMT1-MMP signal sequence is linked by the short linker
PVAT to EGFP. Residues 283–582 of huMT1-MMP containing the
hinge, hemopexin, transmembrane, and cytoplasmic tail were amplified
by PCR using the primers 5-AAAAAAAGATCTTATGGGGGTGAGT-
CAGGGTTCCCCACC-3 (called CHR087) and 5-AAAAGAATTCTCA-
GACCTTGTCCAGCAGGGA-3 (called CHR057). The resulting PCR
product was cloned into the BglII-EcoRI sites of huMT1SSC1 in-frame
with EGFP. All constructs were verified by sequencing using Big Dye
Terminator kit (Applied Biosystems, Warrington, UK).
Cell Culture and Treatments—MCF7 clones stably expressing MT1-
MMP or control clones were generated by transfection of adenocarci-
noma MCF7 with full-length MT1-MMP cDNA or empty vector as
previously described (28). Two clones overexpressing MT1-MMP (MT
clones: MT/1 and MT/3) and two control clones (C10 and C11) were
routinely grown in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% (v/v) fetal calf serum (Invitrogen, Merelbeke, Bel-
gium), penicillin (100 IU/ml), streptomycin (100 g/ml), 2 mM gluta-
mine, 10 mM Hepes buffer, and G418 (400 g/ml). For treatments with
MMP inhibitors or other reagents, cells were seeded in 12-well plates
(Falcon) to a density of 2  105 cells/well and incubated in serum-
containing medium for 24 h. Cells were then washed twice with phos-
phate-buffered saline and subsequently supplemented with 2 ml of
serum-free DMEM (untreated control), BB94, or RO 28-2653 (final
concentration 1 M); rhTIMP-1 (10 g/ml) or rhTIMP-2 (0.1–10 g/ml);
leupeptin (1 M), aprotinin (0.3 M), pepstatin A (1 M), or Pefabloc SC
(1 M); blocking anti-MT1-MMP LEM2 (10 g/ml); genistein (5–50 M),
herbimycin A (0.03–1 M), PD98059 (50 M), SB 203580 (20 M), wort-
mannin (250 nM), or PP2 (1 M). After 24 h of incubation, the resulting
cell monolayers were collected for RNA or proteins extraction. To block
transcription, actinomycin D (10 g/ml) was added after a 12-h incu-
bation in serum-free medium. Cells were harvested before (0 h) or after
several time points (1, 2, 3, 4, 8, or 12 h) following the addition of
actinomycin D, and RT-PCR analysis was performed for VEGF mRNA
and MT1-MMP mRNA expression.
FIG. 2. VEGF mRNA stability in MT
clones and control cells. MT1-MMP
overexpressing clones (MT clones: MT/1
and MT/3) or control clones (C10 and
C11) were incubated in serum-free me-
dium with actinomycin D (10 g/ml) for 0,
1, 2, 3, 4, 8, and 12 h. After RNA extrac-
tion, VEGF and MT1-MMP mRNA levels
were analyzed by RT-PCR using specific
primer and internal synthetic control
RNAs: CTR5 for VEGF, CTR1 for MT1-
MMP, and 28 S as described under “Ex-
perimental Procedures.” The experiment
presented is representative of three inde-
pendent assays. 28 S ribosomal RNA is
shown as a loading control.
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Cell Transfection with Wild Type or Mutated MT1-MMP cDNA—
Stable transfection of MCF7 cells with the different constructs were
performed using the non-liposomal formulation FuGENE-6 transfec-
tion reagent (Roche Applied Science, Indianapolis, IN), according to the
manufacturer’s instructions. Two different vectors containing wild type
MT1-MMP cDNA were used: pc3MT1800s with neomycin (28) or
huMT1-MMP with zeocin (see above) as selected markers, respectively.
Transfectants were selected with Zeocin (100 g/ml) (Invitrogen) or
G418 (400 g/ml) according to the vector used.
Reverse Transcriptase-PCR Analysis—After 24 h of treatment in
serum-free medium, total RNA was extracted from cells by using the
High Pure RNA Isolation Kit (Roche Applied Science). RT-PCR ampli-
FIG. 3. Effect of MMP inhibitors on VEGF-A production. MT1-MMP-overexpressing clones (MT clones: MT/1 and MT/3) or control clones
(C10 and C11) were incubated for 24 h in serum-free medium supplemented with synthetic MMP inhibitors: BB94 or RO 28-2653 (1 M). A, total
RNA of MT clones and control clones were extracted and analyzed by quantitative RT-PCR using standard RNA (CTR1 and CTR5). The histograms
on the right correspond to the scanning quantification of the three different VEGF-A isoforms considered together (“VEGF”). Results are expressed
as the ratio of (VEGF-A mRNAs/synthetic VEGF mRNA (CTR5)) divided by the ratio of (28 S mRNA/synthetic 28 S mRNA (CTR1)). They
correspond to the mean  S.D. of quantifications performed on three independent assays. B, cell lysates were analyzed by immunoblotting using
an anti-VEGF polyclonal antibody. The recombinant human VEGF used as positive control corresponds to a species of 30 kDa.
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fication was performed using the GeneAmp Thermostable rTth reverse
transcriptase RNA PCR kit (Applied Biosystems, Branchburg, NJ),
specific pairs of primers (5 pmol each) (see Table I), 10 ng of total RNA
and, when available, a known copy number of an internal standard
(multiplex synthetic standard RNA, see below) per 25 l of reaction
mixture (final volume). Reverse transcription was performed at 70 °C
for 15 min. For 28 S, MT1-MMP, and TIMP-2 transcripts, PCR ampli-
fication was run as follows: 15 s at 94 °C, 20 s at 68 °C, and 10 s at 72 °C
(number of cycles as indicated in Table I), followed by a final 2-min
extension step at 72 °C. Other cycling conditions are the followings: 20 s
at 94 °C, 20 s at 66 °C, and 30 s at 72 °C for VEGF-A; 20 s at 94 °C, 20 s
at 60 °C, and 30 s at 72 °C for VEGF-B; 15 s at 94 °C, 20 s at 55 °C, and
15 s at 72 °C for VEGF-C and VEGF-D. For VEGF-R1, VEGF-R2, and
neuropilin-1: 15 s at 94 °C, 30 s at 60 °C, and 30 s at 72 °C. For PlGF,
Tie-2, and ang-1: 15 s at 94 °C, 30 s at 60 °C, and 15 s at 72 °C. RT-PCR
products were resolved on 10% polyacrylamide gels and analyzed using
a Fluor-S MultiImager (Bio-Rad, Hercules, CA) after staining with
Gelstar dye (FMC BioProducts, Rockland, ME). The selected primer
pairs for each human mRNA are described in Table I; their selectivity
and efficiency were tested by RT-PCR using 10 ng of total RNA ex-
tracted from human placenta or human dermal fibroblasts or 50 ng of
human DNA as negative control. For RT-PCR quantification of
VEGF-B, -C, -D, PlGF, VEGFR1, VEGFR2, neuropilin, angiopoietin-1,
and Tie2, their expression was normalized to 28 S rRNA. For a more
precise quantification of MT1-MMP, TIMP-2, VEGF mRNA, and 28 S
rRNA, synthetic standard RNAs were generated as previously de-
scribed (28, 34, 35). These synthetic RNAs have two main characteris-
tics. First, they can be amplified by primers used for RT-PCR amplifi-
cation of the endogenous mRNA of interest. Second, the size of their
amplification product is different from the size of the RT-PCR product
amplified from the mRNA, permitting their discrimination after elec-
trophoresis. The ratio between the signals for a specific mRNA and the
standard RNA was shown to increase linearly with the amount of
cellular RNA.
FIG. 4. Effect of protease inhibitors,
recombinant TIMP-1, TIMP-2, and
blocking anti-MT1-MMP on the
VEGF-A expression. A clone overex-
pressing MT1-MMP (MT/1) and a control
clone (C10) were incubated for 24 h in
serum-free medium supplemented with
leupeptin (1 M), aprotinin (0.3 M), pep-
statin A (1 M), or Pefabloc SC (1 M) (A),
recombinant TIMP-1 (10 g/ml), or differ-
ent concentrations of recombinant
TIMP-2 (0.1, 1, and 10 g/ml) (B), or with
blocking anti-MT1-MMP LEM2 (10 g/
ml) (C). The histograms correspond to the
quantification (mean  S.D.) of RT-PCR
analysis of VEGF-A performed on two as-
says (see legend of Fig. 3).
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Western Blotting Analysis—Total cell extracts were prepared by in-
cubating cells in radioimmune precipitation assay buffer (50 mM Tris-
HCl, pH 7.4; 150 mM NaCl; 1% Nonidet P40; 1% Triton X-100; 1%
sodium deoxycholate; 0.1% SDS; 5 mM iodoacetamide; 2 mM phenyl-
methylsulfonyl fluoride). After centrifugation at 15,000 rpm for 30 min,
at 4 °C, the supernatant was stored frozen at 20 °C. Protein concen-
tration was determined by using the DC protein Assay Kit (Bio-Rad
Laboratories, Hercules, CA) and adjusted to 2 mg/ml. Samples of total
cell extracts were resolved by SDS-PAGE under reducing conditions,
and proteins were transferred to nitrocellulose membranes (Hybond-
ECL membrane, Amersham Biosciences, Arlington Heights, IL). The
membranes were exposed to primary mouse monoclonal antibody 2D-7
raised against the hemopexin-like domain of MT1-MMP (kindly pro-
vided by M.-C. Rio, Instit de Genetique et de Biologie Moleculaire et
Cellulaire, Illkirch, France) (28) or rabbit polyclonal antibody against
human VEGF165, -189, and -121 amino acid splice variants at dilution
of 1/500 ((A-20):sc-152 Sanver Tech). After extensive washings, the
membranes were incubated with a secondary horseradish peroxidase-
conjugated goat anti-mouse (for MT1-MMP) or mouse anti-rabbit anti-
body (for VEGF) at 1/1000 (DAKO, Glostrup, Denmark). Signals were
detected using an enhanced chemiluminescence (ECL) kit
(PerkinElmer Life Sciences, Boston), according to the manufacturer’s
instructions.
Gelatin Zymography—Conditioned media were prepared by incubat-
ing subconfluent cells (2  105) in 24 well-plates (Falcon, BD Bio-
sciences) for 24 h, in serum-free DMEM, in the presence of an exoge-
nous source of MMP-2 (medium conditioned by Chinese hamster ovary
cells transfected with full-length MMP-2 cDNA) (36). Conditioned me-
dia were harvested, clarified by centrifugation, and stored frozen at
20 °C. Aliquots (5–10 l) of conditioned media standardized for cell
DNA content were mixed with equal volume of non-reducing sample
buffer (62.5 mM Tris-HCl, pH 6.8; 2% SDS; 10% glycerol; 0.1% brom-
phenol blue) and were resolved on 10% gels SDS-PAGE containing 0.1%
gelatin (w/v) according to the procedure previously described (27).
Densitometric Analysis—Gels were analyzed with Quantity One soft-
ware (version 4.2.2., Bio-Rad Laboratories, Hercules, CA) after densi-
tometry scanning of the gels using a Fluor-S MultiImager (Bio-Rad).
RESULTS
MT1-MMP Overexpression Is Associated with a Specific Up-
regulation of VEGF-A—We first examined the possibility that
several angiogenic factors and their receptors could be a target
of the up-regulatory effect of MT1-MMP. We have used human
breast adenocarcinoma MCF7 clones stably transfected with
MT1-MMP cDNA (MT/1 and MT/3 clones, designed “MT
clones”) and control MCF7 cells stably transfected with control
vector (C10 and C11 clones called “control clones”) (28). We
examined by RT-PCR analysis the expression of different forms
of VEGF (VEGF-A, -B, -C, -D), PlGF, their receptors (VEGF-
R1, VEGF-R2), neuropilin-1 (NRP-1), angiopoietin-1, its recep-
tor Tie2 and TIMP-2. In accordance with our previous data
(28), the mRNA levels of three isoforms of VEGF-A (VEGF121,
VEGF165 and VEGF189) were 2- to 3-fold increased in MT
clones as compared with control clones (Fig. 1). In sharp con-
trast, no modulation of the expression of VEGF-C, VEGF-D,
VEGF-R2, NRP-1, Ang-1, Tie2, or TIMP-2 was induced by
MT1-MMP expression. In our conditions, PlGF, VEGF-B, and
VEGF-R1 were never detected in the clones analyzed. These
findings emphasize the specific effect of MT1-MMP on the
mRNA expression of the three VEGF-A isoforms (VEGF121,
VEGF165, and VEGF189) without affecting the expression of
other angiogenic factors.
MT1-MMP Overexpression Does Not Affect VEGF mRNA
Stability—To determine whether MT1-MMP overexpression
affects VEGF mRNA stability, we evaluated the effect of acti-
nomycin D, an inhibitor of RNA transcription, on the evolution
of VEGF mRNA levels in the different clones expressing or not
MT1-MMP. In the absence of actinomycin D, the VEGF mRNA
expression was increased 3-fold in MT clones as compared with
control clones (Fig. 2). In the presence of actinomycin D, VEGF
mRNA levels decreased progressively with time and in a sim-
ilar manner in both MT clones. Almost no VEGF mRNA re-
mained after 3 h of actinomycin D treatment, whereas MT1-
MMP mRNAs persisted until 8 h and was not anymore detected
after 12 h (Fig. 2). These results demonstrate that the VEGF
FIG. 5. Analysis of signaling pathways involved in VEGF up-
regulation by MT1-MMP. MT1-MMP-overexpressing clones (MT
clones: MT/1 and MT/3) and control clones (C10 and C11) were treated
with various pharmacological inhibitors specific to different signaling
pathways. A, one MT clone (MT/3) and one control clone (C10) were
treated with PD98059 (50 M), wortmannin (250 nM), or herbimycin A.
B, one MT clone (MT/1) and one control clone (C12) were treated with
PD98059 (50 M), herbimycin A (250 nM), or SB203580 (20 M). C, two
MT clones and two control clones were treated with genistein (10 M).
After 24 h of treatment without serum, the expression of VEGF mRNA
was measured by RT-PCR. The experiments presented are representa-
tive of two different assays performed in triplicate. 28 S ribosomal RNA
is shown as a loading control.
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up-regulation by MT1-MMP could not result from an enhance-
ment of mRNA stability but to a transcriptional activation.
VEGF Up-regulation by MT1-MMP Is Blocked by MMP In-
hibitors—To determine whether MT1-MMP activity is required
for VEGF regulation, the effect of synthetic (BB94 and RO
28-2653) or recombinant physiological inhibitors (rTIMP-1 and
rTIMP-2) on VEGF expression was examined in MT and con-
trol clones. Although the treatment of cells with BB-94 or RO
28-2653 (1 M) inhibitors reduced VEGF mRNA levels in MT
clones, it did not affect the basal VEGF mRNA levels in control
clones (Fig. 3A). Quantitative RT-PCR analysis using synthetic
standard mRNAs revealed that treatment of MT clones with
both inhibitors down-regulated VEGF mRNA production to the
levels found in control clones (Fig. 3A). The inhibition of VEGF
production in cells treated with BB94 was confirmed by meas-
uring VEGF at a protein level by Western blot analysis (Fig.
3B). To assess the effect of physiological MMP inhibitors on
VEGF regulation, cells were incubated for 24 h with rhTIMP-1
(10 g/ml), which is unable to inhibit MT1-MMP activity or
with increasing concentrations of rhTIMP-2 (0.1, 1, and 10
g/ml), which binds MT1-MMP (Fig. 4B). TIMP-2 decreased
significantly the level of VEGF mRNAs in MT clones when
used at 10 g/ml but not at lower concentrations (0.1 and 1
g/ml). In sharp contrast, TIMP-1 did not affect VEGF expres-
sion. These findings suggest the importance of the enzymatic
activity of MT1-MMP in the transcriptional regulation of
VEGF. The specificity of MT1-MMP as compared with other
proteases, was assessed by using different protease inhibitors.
Inhibitors of serine proteases (aprotinin and Pefabloc SC), cys-
tein and serine proteases (leupeptin), or cathepsin and aspartic
proteases (pepstatin A) failed to modulate the VEGF expres-
sion (Fig. 4A). In sharp contrast, specific anti-MT1-MMP block-
ing antibody (LEM2) reduced VEGF mRNA levels to that ob-
served in control clones (Fig. 4C).
VEGF Up-regulation by MT1-MMP Involves Nonreceptor Src
Tyrosine Kinases—To provide further insights into the mecha-
nisms underlying the up-regulating effect of MT1-MMP on
VEGF, cells were cultured in the presence of several inhibitors
of different signaling pathways, and the levels of VEGF were
examined by RT-PCR analysis. As illustrated in Fig. 5 (A and
B), neither the phosphatidylinositol 3-kinase pathway inhibitor
(wortmannin), the MAPK/ERK kinase pathway inhibitor
(PD98059), nor the p38 MAPK pathway inhibitor (SB203580)
affected MT1-MMP-mediated VEGF induction. In contrast,
herbimycin-A, an inhibitor of tyrosine kinase, strongly inhib-
ited the up-regulating effect of MT1-MMP. Similarly to herbi-
mycin-A, genistein, another tyrosine kinase inhibitor markedly
suppressed the VEGF mRNA induction in MT clones without
affecting the VEGF expression in control clones (Fig. 5C).
The VEGF mRNA expression in MT clones was not signifi-
cantly affected by herbimycin-A used at doses ranging from 60
to 125 nM, but was reduced to a basal level by herbimycin-A at
250 nM (Fig. 6A). Incubation of MT clones with increasing
concentration of genistein (5–50 M) decreased VEGF expres-
FIG. 6. Effect of herbimycin A on
VEGF up-regulation by MT1-MMP.
One MT1-MMP-overexpressing clone (MT
clone: MT/1) and one control clone (C10)
were incubated with increasing concen-
trations of herbimycin A (0–1000 nM). A,
VEGF and MT1-MMP mRNA levels were
analyzed by RT-PCR. The histograms cor-
respond to the quantification of VEGF
mRNA in MT1-MMP clones treated or not
with herbimycin A (mean  S.D. of three
different experiments) (see legend of Fig.
3). B, Western blot analysis of VEGF pro-
duction in MT clones treated or not with
250 nM or 1 M of herbimycin A, using an
anti-VEGF polyclonal antibody. Similar
results were obtained with the other MT
clone (MT/3) and control clone (C11)
(data not shown).
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sion in a dose-dependent manner (Fig. 7A). Interestingly, MT1-
MMP expression levels were not affected by the different con-
centrations of herbimycin or genistein used (Figs. 6A and 7A).
In addition, VEGF expression in control clones was never mod-
ulated by herbimycin-A or genistein at the different concentra-
tions used (Figs. 6A and 7A). In accordance to RT-PCR data,
the inhibition of VEGF up-regulation in MT clones by herbi-
mycin-A and genistein was confirmed at protein level by West-
ern blotting (Figs. 6B and 7B).
To further investigate the tyrosine kinase pathway, we
tested a specific inhibitor of Src protein, 4-amino-5-(4-chloro-
phenyl)-7-(t-butyl)pyrazol[3,4-d]pyrimidine (PP2, 1 M) (37).
Similarly to herbimycin and genistein, PP2 abolished the
VEGF up-regulation without affecting MT1-MMP expression
(Fig. 8). These results indicated that VEGF up-regulation in
MT clones was depend on nonreceptor Src tyrosine kinases.
VEGF Up-regulation Requires MT1-MMP Catalytic and Cy-
toplasmic Domain—Because catalytic and cytoplasmic do-
mains of MT1-MMP have been shown to be important for
pro-MMP2 activation, we investigated their respective require-
ment for VEGF regulation. Therefore, we generated different
MT1-MMP constructs encoding proteins with deletions in the
catalytic domain (cd) or the cytoplasmic domain (577) (Fig.
9A). In addition, we designed four MT1-MMP mutants with a
substitution in the active site (E240A) or in the cytoplasmic
domain (S577A, C574S, or T567A) (Fig. 9A). These constructs
and wild type MT1-MMP cDNA were transfected in MCF7 cells
and stable cell populations were selected by antibiotic treat-
ment. MT1-MMP production was assessed both at protein and
mRNA levels by Western blotting (data not shown) and RT-
PCR analysis (Fig. 9C). The capacity of WT and mutated forms
of MT1-MMP expressed by these cells to process pro-MMP2
was evaluated by zymographic analysis performed on medium
conditioned by transfected cells incubated with exogenous pro-
MMP2 (Fig. 9B). As expected, MT1-MMP forms with the cata-
lytic domain deleted (cd) as well as inactive MT1-MMP (MT1-
E240A), were both unable to activate exogenous pro-MMP2.
Pro-MMP2-activating capacity was not affected by deletion or
two point mutations (S577A or T567A) in the cytoplasmic tail.
However, mutation at position 574 (MT1-C574S) led to a re-
duction of pro-MMP2 activation (Fig. 9C). RT-PCR analysis
indicated a 2- to 3-fold increased levels of VEGF mRNA in cells
transfected with WT MT1-MMP cDNA as compared with cells
transfected with control vector (Fig. 9D). Transfection with two
FIG. 7. Effect of genistein on VEGF
up-regulation by MT1-MMP. One
MT1-MMP-overexpressing clone (MT
clone: MT/1) and one control clone (C10)
were incubated with increasing concen-
trations of genistein (0–50 M). A, VEGF
and MT1-MMP mRNA levels were ana-
lyzed by RT-PCR (see legend of Fig. 3).
The histograms correspond to the quanti-
fication of VEGF mRNA (mean  S.D. of
three independent assays) (see legend of
Fig. 3). B, Western blot analysis of VEGF
production in MT clones treated or not
with 5 M or 10 M of genistein, using an
anti-VEGF polyclonal antibody. Similar
results were obtained with the other MT
clone (MT/3) and control clone (C11)
(data not shown).
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mutated forms (S577A or T567A) led to a similar VEGF up-
regulation. In sharp contrast, no up-regulation of VEGF ex-
pression was detected in cells expressing deleted forms of MT1-
MMP (MT1-cd and MT1-577), or MT1-MMP mutated at
position 574 (MT1-C574S). Similarly, cell transfection with
enzymatically inactive MT1-MMP cDNA (E240A) failed to in-
duce VEGF mRNA expression.
DISCUSSION
In addition to its direct role on pro-MMP activation and
extracellular matrix degradation, emerging functions of MT1-
MMP include at least the activation and/or shedding of cell
surface molecules (21–23). We and others provided evidence
that MT1-MMP and VEGF can be functionally linked in tu-
moral angiogenesis (7). In support of this functional link is the
fact that hypoxia-induced up-regulation of MT1-MMP in mu-
rine bone marrow-derived stromal cells correlates with a stim-
ulation of VEGF (38). However, the mechanisms underlying
VEGF production in response to MT1-MMP overexpression
remain to be elucidated. In this work, we demonstrate a specific
effect of MT1-MMP on VEGF-A expression without affecting
other members of VEGF family or their receptors. This MT1-
MMP effect is dependent on the presence of functional catalytic
and cytoplasmic domains of the enzyme and involves the activ-
ity of Src tyrosine kinases.
By RT-PCR analysis, we demonstrate that MT1-MMP over-
expression specifically up-regulated VEGF-A, whereas the
mRNA levels of other VEGF family members (VEGF-C and -D)
and their receptors (VEGF-R2, NRP-1, Ang-1, and Tie-2) were
not affected. The mRNA for VEGF-B, PlGF, and VEGF-R1
were not expressed either in MCF7 parental cells or in MT
clones. This specific correlation between MT1-MMP and
VEGF-A is in agreement with in vivo observation in glioma
tissue samples (30, 39). In the present study, we provide evi-
dence that this specific regulation of VEGF-A production by
MT1-MMP occurred at a transcriptional level without a con-
comitant increase in VEGF mRNA stability. The specific effect
of MT1-MMP was assessed by using a blocking MT1-MMP
antibody.
The localization of MT1-MMP at the surface of some cells in
clathrin-coated pits (40) and caveolae (41–43) raised the pos-
sibility that MT1-MMP activates intracellular signaling events
(8). By using a series of specific inhibitors for different signal-
ing pathways putatively involved in VEGF regulation, we
found that the activation of MAPK/ERK kinase, p38 MAPK, or
phosphatidylinositol 3-kinase pathways is not required for
VEGF up-regulation in our experimental conditions. Interest-
ingly, herbimycin A or genistein, both selective inhibitors of
protein tyrosine kinases, suppressed VEGF up-regulation in
MT clones, without affecting VEGF mRNA levels in control
clones. In addition, PP2, a specific inhibitor of Src tyrosine
kinases, also strongly abolished the VEGF up-regulation in MT
clones. The possibility of a nonspecific toxic effect of the inhib-
itors was excluded, because mRNA levels for MT1-MMP were
not altered in the presence of inhibitors. The finding that an
Src tyrosine kinase inhibitor is effective in blocking VEGF
transcription agrees with reports indicating that these nonre-
ceptor kinases participate in VEGF induction by hypoxia (44,
45), adrenergic stimulation (37), or prostaglandin PGE2 (46).
Our data indicate that the pathway through which MT1-MMP
regulates VEGF is distinct to that implicated in the induction
of cell migration which involves extracellular signal-regulated
protein kinase (ERK) (47). In addition, MT1-MMP has been
shown to control integrin maturation by processing the V
integrin subunit, leading to tyrosine phosphorylation of focal
adhesion kinase and thereby to cell migration (48). The involve-
ment of such an V convertase activity by MT1-MMP and an
indirect activation of focal adhesion kinase pathway is unlikely
in our model, because MCF7 cells failed to produce V3 (7).
Altogether these data indicate that MT1-MMP can contribute
to the activation of different intracellular pathways leading to
distinct biological responses.
Deletion of the six C-terminal amino acids of the cytoplasmic
domain or mutation of Cys-574 (C574S) completely abolished
VEGF up-regulation suggesting that the integrity of specific
sites of the cytoplasmic tail of MT1-MMP is essential for proper
VEGF stimulation. In sharp contrast, S577A and T567A mu-
tants retained their ability to increase VEGF expression. These
results highlight the importance of cysteine residue at position
574 in the MT1-MMP cytoplasmic tail. This amino acid residue
has been reported to be essential for the formation of a disulfide
bridge linking two MT1-MMP molecules (49). Such homophilic
complex formation is thought to be involved in pro-MMP-2
activation (18, 49). Accordingly, we observed by zymographic
analysis that the substitution of Cys-574 residue by Ser in
MT1-MMP led to a reduction of exogenous pro-MMP2 activa-
tion. However, because MCF7 cells do not express pro-MMP2
(7), it is likely that this enzyme is not involved in VEGF
up-regulation. Furthermore, no correlation could be estab-
lished between the capacity to activate pro-MMP2 and the
up-regulation of VEGF. Indeed, although the deletion of the six
C-terminal amino acids of MT1-MMP failed to affect pro-MMP2
activation, it inhibited VEGF up-regulation.
Whether the regulation of gene expression by MT1-MMP
occurs directly or indirectly by regulating other cell surface
receptors remains to be demonstrated. Recently, Kajita et al.
(23) reported that the shedding of the hyaluronate receptor
(CD44) ectodomain by MT1-MMP resulted in enhanced cell
migration. On the other hand, Okamoto et al. (50) showed that
CD44 cell surface shedding could be followed by an intracellu-
FIG. 8. Effects of tyrosine kinases and Src-type tyrosine ki-
nases on VEGF and MT1-MMP expression. Representative inhibi-
tion of VEGF-A up-regulation in one MT1-MMP overexpressing clone
(MT clone: MT/1) and one control clone (C10) incubated with herbimy-
cin (1 M), genistein (10 M) or PP2 (1 M). MT1-MMP expression of the
MT clone was not affected by cell treatment. The mRNA levels of VEGF,
MT1-MMP, and 28 S were analyzed by RT-PCR as described under
“Experimental Procedures.”
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lar cleavage resulting in the release of CD44 intracellular do-
main translocating to the nucleus and promoting gene tran-
scription. A putative link between MT1-MMP-induced
shedding of CD44 and gene expression remains to be estab-
lished. However, these findings raised the possibility that proc-
essing of a cell surface receptor by MT1-MMP might induce a
subsequent intracellular signaling.
The catalytic activity of MT1-MMP appears to be important
for VEGF mRNA up-regulation, because this effect was mark-
edly reduced by synthetic (BB94 and RO 28-2653) and physio-
logical (TIMP-2) MMP inhibitors, as well as by deletion of or
point mutation (E240A) within the catalytic domain of the
enzyme. The lack of inhibitory effect of TIMP-1 even at high
concentration is in favor of a specific role of MT1-MMP without
involvement of other MMPs. Accordingly, in vitro tubular for-
mation of endothelial cells within fibrin gels was inhibited in
the presence of high concentration of TIMP-2 (10 g/ml) but not
of TIMP-1 (26). In addition, the present data confirm our pre-
vious demonstration that the in vivo anti-angiogenic effect of
TIMP-2 in murine mammary carcinoma cells was associated
with a strong reduction of VEGF expression (35). Accordingly,
synthetic broad spectrum MMP inhibitors also down-regulated
in vivo VEGF expression in a T cell lymphoma model (51).
Therefore, our data demonstrate that, for VEGF up-regulation,
both the catalytic and cytoplasmic domains of MT1-MMP are
essential. This observation is in accordance with the role of
FIG. 9. Effect of MT1-MMP mutations on VEGF-A expression. A, schematic representation of different mutated forms of MT1-MMP cDNA
constructs. Full-length MT1-MMP (wild-type (wt)) contains a signal peptide, a prodomain (Pro), a furin cleavage site (“Furin”), a catalytic domain
(“Catalytic”), a hinge region, a hemopexin-like domain (“Hemopexin”), a transmembrane domain (TM), and a cytoplasmic tail (CT). The 577 form
corresponds to the deletion of six amino acids in the cytoplasmic tail. The cd form is characterized by replacement of the prodomain and the entire
catalytic domain by EGFP. MT1-MMP forms with point mutations are: S577A (serine 577 substituted by alanine); C574S (cysteine 574 replaced
by serine); T567A (threonine 567 substituted by alanine); and inactive E240A (glutamic acid 240 replaced by alanine in the catalytic domain).
MCF7 cells were stably transfected with vectors containing either neomycin (“neo”) or zeocin (“Zeo”) for selection. Cell populations were obtained
after transfection with empty vector (“CTR/neo” or “CTR/Zeo”), vector containing full-length MT1-MMP cDNA (“WT/neo” or “WT/Zeo”),
or mutated MT1-MMP cDNA as described under “Experimental Procedures.” B, zymographic analysis of medium conditioned by transfected cells
incubated in the presence of an exogenous source of pro-MMP2. The medium conditioned by MT/1 clone was used as positive control. C, RT-PCR
analysis of MT1-MMP and VEGF-A in selected populations. The 28 S ribosomal RNA is shown as a loading control. CTR1 corresponds to synthetic
internal control RNA for 28 S rRNA. Histograms correspond to the quantification of VEGF and MT1-MMP mRNA (see Fig. 3 legend).
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both domains of this enzyme in signal transduction through
ERK activation pathway (47).
Altogether, our data support the recently emerging concept
of a functional link between TIMPs, MMPs, and VEGF. Al-
though TIMP1 has been shown to up-regulate VEGF expres-
sion in some cells (52), TIMP-3 can inhibit angiogenesis by
blocking VEGF binding to VEGFR-2 (53). The control of VEGF
bioactivity by MMPs is supported by the findings that MMP-9
induces the release of VEGF from the extracellular matrix (54).
In addition, MMP-1, -3, -7, and -13 selectively degrade connec-
tive tissue growth factor bound to VEGF165 and thereby pro-
mote the angiogenic activity of VEGF165 (55).
In conclusion, our work provides new insights into the mech-
anisms of MT1-MMP action during tumoral angiogenesis.
MT1-MMP controls VEGF expression at a transcriptional level
through the activation of Src-tyrosine kinase pathway. This
effect depends on both the presence of the catalytic and cyto-
plasmic domains. These results strengthen the emerging view
that the role of MT1-MMP in tumor progression is not strictly
restrained to its classical role in activation of pro-MMPs and
matrix destruction but also to the control of gene expression.
Such findings have direct impact in cancer therapy by provid-
ing a possibility to trigger simultaneously VEGF production
and tissue remodeling associated with tumoral angiogenesis by
inhibiting MT1-MMP.
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